Docoh
Loading...

NBTX Nanobiotix

News

From Benzinga Pro
58 Biggest Movers From Yesterday
7 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe is no long active.
12 Health Care Stocks Moving In Thursday's Intraday Session
6 Jan 22
Intraday Update, Markets, Movers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
8 Dec 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
10 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
NANOBIOTIX Highlights Presentation Of New Preclinical Data On NBTXR3 Immune Priming, Checkpoint Inhibitor Combo At Society For Immunotherapy Of Cancer
9 Nov 21
Biotech, News, FDA, Events, General
Data to be presented at the 36th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC) Data show radiotherapy-activated NBTXR3 increased CD8+ T cell infiltration and modulated the T cell receptor
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children
26 Oct 21
Biotech, Earnings, News, Penny Stocks, Health Care, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
NANOBIOTIX Late Sunday Highlighted Presentation Of Phase 1 Expansion Data Evaluating Nbtxr3 As Single Agent Activated By Radiotherapy At Annual Meeting of the American Society for Radiation Oncology
25 Oct 21
Biotech, News, FDA, General
Data presented by Professor Christophe Le Tourneau at the 2021 Annual Meeting of the American Society for Radiation Oncology First survival data from Phase I Dose Expansion in tough-to-treat elderly and frail LA-HNSCC
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
24 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, IPOs, Top Stories
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.

Press releases

From Benzinga Pro
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital
11 Jan 22
Press Releases
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority) Regulatory News: Nanobiotix
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
10 Jan 22
Press Releases
Evaluation of NBTXR3 for global registration in priority head and neck cancer pathway proceeds with the first European patient randomized in global phase III NANORAY-312 study; US and Asia site activation expected in
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
5 Jan 22
Press Releases
First patient randomized in pivotal phase III study evaluating radiotherapy-activated NBTXR3 with or without cetuximab in high-risk elderly patients with locally advanced head and neck squamous cell carcinoma The
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
4 Jan 22
Press Releases
Regulatory News: NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company's
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital
8 Dec 21
Press Releases
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority) Regulatory News: Nanobiotix
NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference
17 Nov 21
Press Releases
Regulatory News: NANOBIOTIX (NASDAQ:NBTX) (PARIS:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today
NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination
9 Nov 21
Press Releases
Data to be presented at the 36th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC) Data show radiotherapy-activated NBTXR3 increased CD8+ T cell infiltration and modulated the T cell receptor
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital
8 Nov 21
Press Releases
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority) Regulatory News: Nanobiotix
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
3 Nov 21
Press Releases
Regulatory News: NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy,
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy
24 Oct 21
Press Releases
Data presented by Professor Christophe Le Tourneau at the 2021 Annual Meeting of the American Society for Radiation Oncology First survival data from Phase I Dose Expansion in tough-to-treat elderly and frail LA-HNSCC